Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Stromal Tumors 1

Interventions

venetoclax 108Azacitidine 92Cytarabine 77Specimen Handling 52fludarabine 47Biopsy 38Daunorubicin 31Cyclophosphamide 31Injections 29Decitabine 29Idarubicin 27fludarabine phosphate 25Granulocyte Colony-Stimulating Factor 22Busulfan 22Whole-Body Irradiation 20Mycophenolic Acid 20Tacrolimus 18decitabine and cedazuridine drug combination 17Melphalan 17CPX-351 17Stem Cell Transplantation 16gilteritinib 14Mitoxantrone 14ivosidenib 13Filgrastim 13Peripheral Blood Stem Cell Transplantation 12Cladribine 12Magnetic Resonance Spectroscopy 11Etoposide 11Cyclosporine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × olverembatinib × 90 days × Clear all
NCT04501120 2026-04-29

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Ascentage Pharma Group Inc.

Phase 1/2 Recruiting
682 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡